{"product_id":"lucifezo-fezolinetant","title":"LuciFezo (Fezolinetant)","description":"\u003ch2\u003eAbout Fezolinetant\u003c\/h2\u003e\u003cp\u003eFezolinetant  is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause.\u003csup id=\"cite_ref-Veozah_FDA_label_3-3\" class=\"reference\"\u003e\u003c\/sup\u003eIt is a small-molecule, orally active, selective neurokinin-3 (NK\u003csub\u003e3\u003c\/sub\u003e) receptor antagonist which is under development by for the treatment of sex hormone-related disorders.\u003c\/p\u003e\u003ch3\u003eMenopausal Vasomotor Symptoms\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of moderate-to-severe vasomotor symptoms (VMS) caused by menopause\u003c\/p\u003e\u003cp\u003e45 mg PO qDay\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild or moderate (eGFR 30-89 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): No dose adjustment required\u003c\/li\u003e\n\u003cli\u003eSevere (eGFR 15-29 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e or end-stage renal disease [ESRD]): Contraindicated\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eAt baseline\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eALT or AST ≥2x ULN or if total bilirubin elevated (eg, ≥2x ULN): Do not start therapy\u003c\/li\u003e\n\u003cli\u003eMild or moderate (Child-Pugh A or B): Increased systemic exposure observed; no recommendations listed in prescribing information\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eTreatment-related toxicity\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003e\u003cp\u003eALT\/AST \u0026gt;5x ULN OR ALT\/AST \u0026gt;3x ULN and total bilirubin \u0026gt;2x ULN: Discontinue\u003c\/p\u003e\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003ch4\u003eMonitoring\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eBefore initiating\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eObtain liver function tests (LFTs) including ALT\/AST, alkaline phosphatase, and total and direct bilirubin\u003c\/li\u003e\n\u003cli\u003eMay initiate if baseline hepatic transaminases \u0026lt;2x ULN and total bilirubin is normal\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eDuring treatment\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMonitor LFTs monthly for the first 3 months, at 6 months, and 9 months after starting therapy\u003c\/li\u003e\n\u003cli\u003ePerform more frequent LFT monitoring (until resolution) if ALT\/AST \u0026gt;3x ULN occur\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797956128811,"sku":"RL20250101s200","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-133.jpg?v=1787022251","url":"https:\/\/xomeds.com\/products\/lucifezo-fezolinetant","provider":"XOMEDS","version":"1.0","type":"link"}